The Form 4 filing, an SEC report of insider stock activity, was submitted on Nov. 3, 2026. The sale took place on Oct. 30, 2026.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-30 |
| Date of Latest Transaction | 2026-10-30 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 1,929 |
| Price | $875.00 |
| Total Transaction Value | $1,687,875.00 |
| Insider | |
| Ticker Symbol | REGN |
| Company | REGENERON PHARMACEUTICALS, INC. |
| Insider Name | BROWN MICHAEL S |
| Insider Title | Director |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 1,380 |
| Position Size Change | 58.30% |
| Filing | |
| Filing Date | 2026-11-03 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of REGN shares, reported under transaction code S. A match in share counts also suggests a link to an exercise or conversion, which can turn an option or another investment into shares.
What was the average price of the transaction?
The average sale price was $875.00 per share.
How did this transaction affect the insider's holdings?
Michael S. Brown sold 1,929 shares and reported 1,380 shares owned afterward. The sale represented 58.30% of his reported shares held before the trade.
What's the total transaction value?
The total value was $1,687,875.00 for the single reported sale.
Are there any special circumstances around this transaction?
Yes. The available information identifies a Rule 10b5-1 plan reference. These plans set trading instructions in advance. The reference may apply to the filing as a whole. No footnote text is available to confirm whether it covers this sale specifically. The plan's start date and trading schedule are unknown.
The sale also matches the number of shares in an exercise or conversion in the same filing. The matching transaction row is unavailable. Equal share counts alone do not confirm matching dates or accounts, or that the exact shares received were sold. They also do not establish how any exercise was paid for.
For research purposes only; not investment advice.